Medtronic Secured CE Mark Approval for its Minimed™ 780G System, Extending its use to Insulin-Requiring Individuals With Diabetes, Including Children as Young as two Years old, Pregnant Women, and Patients with Type 2 Diabetes
On July 21, 2025, Medtronic plc., a global medical technology leader, secured the CE Mark in Europe to allow the MiniMed™ 780G system to be used in children as young as 2 years old, pregnant women, and individuals with insulin-requiring type 2 diabetes. The approval followed a review of published clinical studies involving toddlers, expectant mothers, and type 2 diabetes patients. This regulatory milestone reflected Medtronic’s dedicati...